Current small animal models for LASV hearing loss

Rachel A. Sattler, Junki Maruyama, Nathan Y. Shehu, Tomoko Makishima, Slobodan Paessler

Research output: Contribution to journalReview article

Abstract

Lassa virus (LASV) is endemic in West Africa, causing an estimated 100 000–300 000 new infections and up to 5000–10 000 deaths yearly. There are no vaccines and therapeutics are extremely limited. Typical case fatality rates are ∼1%, although a recent 2018 Nigerian outbreak featured an unprecedented 25.4% case fatality rate. Survivors of infection suffer a lifetime of sequelae with sudden onset sensorineural hearing loss (SNHL) being the most prevalent. The cause of this hearing loss remains unknown, and there is a critical need for further research on its mechanisms and potential therapeutics. The objective of this review is to outline the only currently available small animal model for LASV-induced hearing loss and to identify potential surrogate models.

Original languageEnglish (US)
Pages (from-to)118-122
Number of pages5
JournalCurrent Opinion in Virology
Volume37
DOIs
StatePublished - Aug 1 2019

Fingerprint

Lassa virus
Hearing Loss
Animal Models
Western Africa
Mortality
Sensorineural Hearing Loss
Infection
Disease Outbreaks
Survivors
Vaccines
Therapeutics
Research

ASJC Scopus subject areas

  • Virology

Cite this

Current small animal models for LASV hearing loss. / Sattler, Rachel A.; Maruyama, Junki; Shehu, Nathan Y.; Makishima, Tomoko; Paessler, Slobodan.

In: Current Opinion in Virology, Vol. 37, 01.08.2019, p. 118-122.

Research output: Contribution to journalReview article

@article{5bce2118bafe49a699d04f549c91097d,
title = "Current small animal models for LASV hearing loss",
abstract = "Lassa virus (LASV) is endemic in West Africa, causing an estimated 100 000–300 000 new infections and up to 5000–10 000 deaths yearly. There are no vaccines and therapeutics are extremely limited. Typical case fatality rates are ∼1{\%}, although a recent 2018 Nigerian outbreak featured an unprecedented 25.4{\%} case fatality rate. Survivors of infection suffer a lifetime of sequelae with sudden onset sensorineural hearing loss (SNHL) being the most prevalent. The cause of this hearing loss remains unknown, and there is a critical need for further research on its mechanisms and potential therapeutics. The objective of this review is to outline the only currently available small animal model for LASV-induced hearing loss and to identify potential surrogate models.",
author = "Sattler, {Rachel A.} and Junki Maruyama and Shehu, {Nathan Y.} and Tomoko Makishima and Slobodan Paessler",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.coviro.2019.08.001",
language = "English (US)",
volume = "37",
pages = "118--122",
journal = "Current Opinion in Virology",
issn = "1879-6257",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Current small animal models for LASV hearing loss

AU - Sattler, Rachel A.

AU - Maruyama, Junki

AU - Shehu, Nathan Y.

AU - Makishima, Tomoko

AU - Paessler, Slobodan

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Lassa virus (LASV) is endemic in West Africa, causing an estimated 100 000–300 000 new infections and up to 5000–10 000 deaths yearly. There are no vaccines and therapeutics are extremely limited. Typical case fatality rates are ∼1%, although a recent 2018 Nigerian outbreak featured an unprecedented 25.4% case fatality rate. Survivors of infection suffer a lifetime of sequelae with sudden onset sensorineural hearing loss (SNHL) being the most prevalent. The cause of this hearing loss remains unknown, and there is a critical need for further research on its mechanisms and potential therapeutics. The objective of this review is to outline the only currently available small animal model for LASV-induced hearing loss and to identify potential surrogate models.

AB - Lassa virus (LASV) is endemic in West Africa, causing an estimated 100 000–300 000 new infections and up to 5000–10 000 deaths yearly. There are no vaccines and therapeutics are extremely limited. Typical case fatality rates are ∼1%, although a recent 2018 Nigerian outbreak featured an unprecedented 25.4% case fatality rate. Survivors of infection suffer a lifetime of sequelae with sudden onset sensorineural hearing loss (SNHL) being the most prevalent. The cause of this hearing loss remains unknown, and there is a critical need for further research on its mechanisms and potential therapeutics. The objective of this review is to outline the only currently available small animal model for LASV-induced hearing loss and to identify potential surrogate models.

UR - http://www.scopus.com/inward/record.url?scp=85071567330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071567330&partnerID=8YFLogxK

U2 - 10.1016/j.coviro.2019.08.001

DO - 10.1016/j.coviro.2019.08.001

M3 - Review article

AN - SCOPUS:85071567330

VL - 37

SP - 118

EP - 122

JO - Current Opinion in Virology

JF - Current Opinion in Virology

SN - 1879-6257

ER -